Lensar Share Slide on Terminated Merger Deal With Alcon

By Adriano Marchese

Shares of Lensar fell sharply Tuesday after the medical-device company said it won't go forward with its merger with Alcon over concerns the deal wouldn't pass regulatory scrutiny before the pact's deadline.

Shares were trading 30% lower at $7.18, easing from a 52-week low of $6.77 earlier in the morning.

Lensar said late Monday that the companies terminated their deal after concluding they wouldn't secure U.S. regulatory approvals from the Federal Trade Commission in time to close it. The merger agreement was set to expire April 23, with an option to extend to July 23.

The deal was originally signed in March of last year when Alcon agreed to acquire Lensar in a deal worth about $430 million, or $14 a share.

Lensar said it will retain the $10 million deposit contemplated by the merger agreement.

Alcon shares fell 0.6% to $77.32.

Write to Adriano Marchese at [e-mail]

(END) Dow Jones Newswires

03-17-26 1042ET